Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A
The generation of an antibody response capable of neutralizing a broad range of clinical isolates remains an important goal of human immunodeficiency virus type 1 (HIV-1) vaccine development. Envelope glycoprotein (Env)-based vaccine candidates will also need to take into account the extensive genet...
Gespeichert in:
| Veröffentlicht in: | AIDS research and human retroviruses 2006-06, Vol.22 (6), p.569-579 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 579 |
|---|---|
| container_issue | 6 |
| container_start_page | 569 |
| container_title | AIDS research and human retroviruses |
| container_volume | 22 |
| creator | Beddows, Simon Kirschner, Marc Campbell-Gardener, Lila Franti, Michael Dey, Antu K Iyer, Sai Prasad N Maddon, Paul J Paluch, Maciej Master, Aditi Overbaugh, Julie VanCott, Thomas Olson, William C Moore, John P |
| description | The generation of an antibody response capable of neutralizing a broad range of clinical isolates remains an important goal of human immunodeficiency virus type 1 (HIV-1) vaccine development. Envelope glycoprotein (Env)-based vaccine candidates will also need to take into account the extensive genetic diversity of circulating HIV-1 strains. We describe here the generation of soluble, stabilized, proteolytically cleaved, trimeric forms of Env (SOSIP gp140 proteins) based on contemporary Env subtype A viruses from East Africa. We discuss issues associated with the construction, purification, and characterization of such complex proteins; not all env sequences allow the expression of trimeric proteins. However, stabilized trimers from one such protein, KNH1144 SOSIP gp140, were successfully made. These proteins are now being prepared for preclinical immunogenicity studies. |
| doi_str_mv | 10.1089/aid.2006.22.569 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68568710</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19457459</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-8bbf5957d2c26a75f463a768eba51857a9421095cf4b9b3bd8db7ae2255609743</originalsourceid><addsrcrecordid>eNqFkc9LwzAUx4Mobk7P3iQnT2uXpM2v4xjTCQMv6jUkaYqVrp1NOtjA_92sG3j0FF7yeV9e3geAe4xSjISc6apICUIsJSSlTF6AMZYZTkSO6CUYIyFkQgiRI3Dj_RdCSBJCr8EIMy4ZzcgY_Czaxoeut6FqG6ibAtpP3WkbXFcd9HDZltC3dW9qN4W2dnrniulA-qBNVVcHV8DQVZvYYeGy2cFt1wZXNR4a7eNbjFi9fMCw3zqIB8D3Zqjmt-Cq1LV3d-dzAt6flm-LVbJ-fX5ZzNeJzQgLiTCmpJLygljCNKdlzjLNmXBGUywo1zInGElqy9xIk5lCFIZrF_9KGZI8zybg8ZQbR_vunQ9qU3nr6lo3ru29YoIywTH6F8QypzynMoKzE2i71vvOlWobV6C7vcJIHdWoqEYd1ShCVFQTOx7O0b3ZuOKPP7vIfgFuIIq6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19457459</pqid></control><display><type>article</type><title>Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Beddows, Simon ; Kirschner, Marc ; Campbell-Gardener, Lila ; Franti, Michael ; Dey, Antu K ; Iyer, Sai Prasad N ; Maddon, Paul J ; Paluch, Maciej ; Master, Aditi ; Overbaugh, Julie ; VanCott, Thomas ; Olson, William C ; Moore, John P</creator><creatorcontrib>Beddows, Simon ; Kirschner, Marc ; Campbell-Gardener, Lila ; Franti, Michael ; Dey, Antu K ; Iyer, Sai Prasad N ; Maddon, Paul J ; Paluch, Maciej ; Master, Aditi ; Overbaugh, Julie ; VanCott, Thomas ; Olson, William C ; Moore, John P</creatorcontrib><description>The generation of an antibody response capable of neutralizing a broad range of clinical isolates remains an important goal of human immunodeficiency virus type 1 (HIV-1) vaccine development. Envelope glycoprotein (Env)-based vaccine candidates will also need to take into account the extensive genetic diversity of circulating HIV-1 strains. We describe here the generation of soluble, stabilized, proteolytically cleaved, trimeric forms of Env (SOSIP gp140 proteins) based on contemporary Env subtype A viruses from East Africa. We discuss issues associated with the construction, purification, and characterization of such complex proteins; not all env sequences allow the expression of trimeric proteins. However, stabilized trimers from one such protein, KNH1144 SOSIP gp140, were successfully made. These proteins are now being prepared for preclinical immunogenicity studies.</description><identifier>ISSN: 0889-2229</identifier><identifier>EISSN: 1931-8405</identifier><identifier>DOI: 10.1089/aid.2006.22.569</identifier><identifier>PMID: 16796532</identifier><language>eng</language><publisher>United States</publisher><subject>Africa, Eastern ; AIDS Vaccines ; AIDS/HIV ; Animals ; Cell Line ; Dimerization ; Drug Design ; env Gene Products, Human Immunodeficiency Virus ; Gene Products, env - chemistry ; Gene Products, env - immunology ; Gene Products, env - isolation & purification ; Gene Products, env - metabolism ; HIV Antibodies - blood ; HIV-1 - classification ; Human immunodeficiency virus 1 ; Humans ; Mice ; Neutralization Tests ; Rabbits</subject><ispartof>AIDS research and human retroviruses, 2006-06, Vol.22 (6), p.569-579</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-8bbf5957d2c26a75f463a768eba51857a9421095cf4b9b3bd8db7ae2255609743</citedby><cites>FETCH-LOGICAL-c326t-8bbf5957d2c26a75f463a768eba51857a9421095cf4b9b3bd8db7ae2255609743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3029,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16796532$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Beddows, Simon</creatorcontrib><creatorcontrib>Kirschner, Marc</creatorcontrib><creatorcontrib>Campbell-Gardener, Lila</creatorcontrib><creatorcontrib>Franti, Michael</creatorcontrib><creatorcontrib>Dey, Antu K</creatorcontrib><creatorcontrib>Iyer, Sai Prasad N</creatorcontrib><creatorcontrib>Maddon, Paul J</creatorcontrib><creatorcontrib>Paluch, Maciej</creatorcontrib><creatorcontrib>Master, Aditi</creatorcontrib><creatorcontrib>Overbaugh, Julie</creatorcontrib><creatorcontrib>VanCott, Thomas</creatorcontrib><creatorcontrib>Olson, William C</creatorcontrib><creatorcontrib>Moore, John P</creatorcontrib><title>Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A</title><title>AIDS research and human retroviruses</title><addtitle>AIDS Res Hum Retroviruses</addtitle><description>The generation of an antibody response capable of neutralizing a broad range of clinical isolates remains an important goal of human immunodeficiency virus type 1 (HIV-1) vaccine development. Envelope glycoprotein (Env)-based vaccine candidates will also need to take into account the extensive genetic diversity of circulating HIV-1 strains. We describe here the generation of soluble, stabilized, proteolytically cleaved, trimeric forms of Env (SOSIP gp140 proteins) based on contemporary Env subtype A viruses from East Africa. We discuss issues associated with the construction, purification, and characterization of such complex proteins; not all env sequences allow the expression of trimeric proteins. However, stabilized trimers from one such protein, KNH1144 SOSIP gp140, were successfully made. These proteins are now being prepared for preclinical immunogenicity studies.</description><subject>Africa, Eastern</subject><subject>AIDS Vaccines</subject><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Cell Line</subject><subject>Dimerization</subject><subject>Drug Design</subject><subject>env Gene Products, Human Immunodeficiency Virus</subject><subject>Gene Products, env - chemistry</subject><subject>Gene Products, env - immunology</subject><subject>Gene Products, env - isolation & purification</subject><subject>Gene Products, env - metabolism</subject><subject>HIV Antibodies - blood</subject><subject>HIV-1 - classification</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>Mice</subject><subject>Neutralization Tests</subject><subject>Rabbits</subject><issn>0889-2229</issn><issn>1931-8405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9LwzAUx4Mobk7P3iQnT2uXpM2v4xjTCQMv6jUkaYqVrp1NOtjA_92sG3j0FF7yeV9e3geAe4xSjISc6apICUIsJSSlTF6AMZYZTkSO6CUYIyFkQgiRI3Dj_RdCSBJCr8EIMy4ZzcgY_Czaxoeut6FqG6ibAtpP3WkbXFcd9HDZltC3dW9qN4W2dnrniulA-qBNVVcHV8DQVZvYYeGy2cFt1wZXNR4a7eNbjFi9fMCw3zqIB8D3Zqjmt-Cq1LV3d-dzAt6flm-LVbJ-fX5ZzNeJzQgLiTCmpJLygljCNKdlzjLNmXBGUywo1zInGElqy9xIk5lCFIZrF_9KGZI8zybg8ZQbR_vunQ9qU3nr6lo3ru29YoIywTH6F8QypzynMoKzE2i71vvOlWobV6C7vcJIHdWoqEYd1ShCVFQTOx7O0b3ZuOKPP7vIfgFuIIq6</recordid><startdate>200606</startdate><enddate>200606</enddate><creator>Beddows, Simon</creator><creator>Kirschner, Marc</creator><creator>Campbell-Gardener, Lila</creator><creator>Franti, Michael</creator><creator>Dey, Antu K</creator><creator>Iyer, Sai Prasad N</creator><creator>Maddon, Paul J</creator><creator>Paluch, Maciej</creator><creator>Master, Aditi</creator><creator>Overbaugh, Julie</creator><creator>VanCott, Thomas</creator><creator>Olson, William C</creator><creator>Moore, John P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200606</creationdate><title>Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A</title><author>Beddows, Simon ; Kirschner, Marc ; Campbell-Gardener, Lila ; Franti, Michael ; Dey, Antu K ; Iyer, Sai Prasad N ; Maddon, Paul J ; Paluch, Maciej ; Master, Aditi ; Overbaugh, Julie ; VanCott, Thomas ; Olson, William C ; Moore, John P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-8bbf5957d2c26a75f463a768eba51857a9421095cf4b9b3bd8db7ae2255609743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Africa, Eastern</topic><topic>AIDS Vaccines</topic><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Cell Line</topic><topic>Dimerization</topic><topic>Drug Design</topic><topic>env Gene Products, Human Immunodeficiency Virus</topic><topic>Gene Products, env - chemistry</topic><topic>Gene Products, env - immunology</topic><topic>Gene Products, env - isolation & purification</topic><topic>Gene Products, env - metabolism</topic><topic>HIV Antibodies - blood</topic><topic>HIV-1 - classification</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>Mice</topic><topic>Neutralization Tests</topic><topic>Rabbits</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beddows, Simon</creatorcontrib><creatorcontrib>Kirschner, Marc</creatorcontrib><creatorcontrib>Campbell-Gardener, Lila</creatorcontrib><creatorcontrib>Franti, Michael</creatorcontrib><creatorcontrib>Dey, Antu K</creatorcontrib><creatorcontrib>Iyer, Sai Prasad N</creatorcontrib><creatorcontrib>Maddon, Paul J</creatorcontrib><creatorcontrib>Paluch, Maciej</creatorcontrib><creatorcontrib>Master, Aditi</creatorcontrib><creatorcontrib>Overbaugh, Julie</creatorcontrib><creatorcontrib>VanCott, Thomas</creatorcontrib><creatorcontrib>Olson, William C</creatorcontrib><creatorcontrib>Moore, John P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS research and human retroviruses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beddows, Simon</au><au>Kirschner, Marc</au><au>Campbell-Gardener, Lila</au><au>Franti, Michael</au><au>Dey, Antu K</au><au>Iyer, Sai Prasad N</au><au>Maddon, Paul J</au><au>Paluch, Maciej</au><au>Master, Aditi</au><au>Overbaugh, Julie</au><au>VanCott, Thomas</au><au>Olson, William C</au><au>Moore, John P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A</atitle><jtitle>AIDS research and human retroviruses</jtitle><addtitle>AIDS Res Hum Retroviruses</addtitle><date>2006-06</date><risdate>2006</risdate><volume>22</volume><issue>6</issue><spage>569</spage><epage>579</epage><pages>569-579</pages><issn>0889-2229</issn><eissn>1931-8405</eissn><abstract>The generation of an antibody response capable of neutralizing a broad range of clinical isolates remains an important goal of human immunodeficiency virus type 1 (HIV-1) vaccine development. Envelope glycoprotein (Env)-based vaccine candidates will also need to take into account the extensive genetic diversity of circulating HIV-1 strains. We describe here the generation of soluble, stabilized, proteolytically cleaved, trimeric forms of Env (SOSIP gp140 proteins) based on contemporary Env subtype A viruses from East Africa. We discuss issues associated with the construction, purification, and characterization of such complex proteins; not all env sequences allow the expression of trimeric proteins. However, stabilized trimers from one such protein, KNH1144 SOSIP gp140, were successfully made. These proteins are now being prepared for preclinical immunogenicity studies.</abstract><cop>United States</cop><pmid>16796532</pmid><doi>10.1089/aid.2006.22.569</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0889-2229 |
| ispartof | AIDS research and human retroviruses, 2006-06, Vol.22 (6), p.569-579 |
| issn | 0889-2229 1931-8405 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68568710 |
| source | Mary Ann Liebert Online Subscription; MEDLINE; Alma/SFX Local Collection |
| subjects | Africa, Eastern AIDS Vaccines AIDS/HIV Animals Cell Line Dimerization Drug Design env Gene Products, Human Immunodeficiency Virus Gene Products, env - chemistry Gene Products, env - immunology Gene Products, env - isolation & purification Gene Products, env - metabolism HIV Antibodies - blood HIV-1 - classification Human immunodeficiency virus 1 Humans Mice Neutralization Tests Rabbits |
| title | Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T21%3A15%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Construction%20and%20characterization%20of%20soluble,%20cleaved,%20and%20stabilized%20trimeric%20Env%20proteins%20based%20on%20HIV%20type%201%20Env%20subtype%20A&rft.jtitle=AIDS%20research%20and%20human%20retroviruses&rft.au=Beddows,%20Simon&rft.date=2006-06&rft.volume=22&rft.issue=6&rft.spage=569&rft.epage=579&rft.pages=569-579&rft.issn=0889-2229&rft.eissn=1931-8405&rft_id=info:doi/10.1089/aid.2006.22.569&rft_dat=%3Cproquest_cross%3E19457459%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19457459&rft_id=info:pmid/16796532&rfr_iscdi=true |